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Abstract  
 
Silica mesoporous nanomaterials have been proved to have meaningful application in 
biotechnology and biomedicine. Particularly, mesoporous bioactive glasses are recently 
gaining importance thanks to their bone regenerative properties. Moreover, the 
mesoporous nature of these materials makes them suitable for drug delivery 
applications, opening new lines in the field of bone therapies. In this work, we have 
developed innovative nanodevices based on the implementation of adenosine 
triphosphate (ATP) and ε-poly-L-lysine molecular gates using a mesoporous bioglass as 
an inorganic support. The systems have been previously proved to work properly with a 
fluorescence probe and subsequently with an antibiotic (levofloxacin) and an 
antitumoral drug (doxorubicin). The bioactivity of the prepared materials has also been 
tested, giving promising results. Finally, in vitro cell culture studies have been carried 
out; demonstrating that this gated devices can provide useful approaches for bone 
cancer and bone infection treatments.  
1. Introduction 
Mesoporous bioactive glasses (MBGs) are a new generation of bioceramics designed 
for bone grafting and skeletal regenerative therapies [1,2]. These biomaterials exhibit 
the bone regenerative properties of bioactive glasses [3], but significantly increased due 
to their high surface area and porosity [4,5]. In addition, MBGs possess ordered 
mesoporous structures similar to those exhibited by pure silica mesoporous materials, 
which makes them excellent candidates as matrixes in drug delivery applications [6–8]. 
This synergy between osteogenic properties and local drug delivery capabilities is called 
to play a main role in field of skeletal therapies in near future. Several studies have been 
carried out to evaluate the behavior of MBGs as drug delivery systems [9], which have 
demonstrated that MBGs can release drugs following classical diffusion mechanism 
[10]. However, the real potential of MBGs remains still unknown. The possibility of 
supplying stimuli-responsive behavior to MBGs, in such a manner that they release the 
payload only when the pathological process occurs is unexplored.  
From a different point of view, and in the context of on-command delivery, mesoporous 
silica has been used as an effective support for the development of controlled-release 
nanodevices because of their unique characteristics, such as high homogeneous porosity, 
inertness, robustness, thermal stability, and high loading capacity [11–14]. 
Consequently, a number of nanodevices for on-command delivery that can be triggered 
by target chemical [15–21], physical [22–26] or biochemical stimuli [27–34] have been 
designed recently. However these gated systems have been mainly developed in 
individual pure silica particles (usually nanometric) [35], and gated functionalities in 
bioactive compositions for bone regenerative purposes are practically unknown [36]. 
In order to explore new bone regeneration strategies, stimuli-responsive 3D 
macroporous scaffolds have been recently prepared by means of incorporating gated 
SiO2 mesoporous nanoparticles within a polymeric matrix [37]. However, as far as we 
are aware, none of these systems have been designed for combining bone regenerative 
properties and on-command drug delivery. The biological response of MBGs can be 
partially tailored by controlling the supramolecular mechanisms that rules the synthesis. 
For instance, we have recently demonstrated that the differentiation of pre-osteoblast 
toward osteoblast phenotype can be enhanced in contact with MBGs prepared with F68, 
a (EO)78-(PO)30-(EO)78 triblock copolymer which acts as a structure directing agent 
[38]. However, the complexity to incorporate the nanogates onto multicomponent SiO2-
CaO-P2O5 systems has hindered perhaps the development of stimuli-responsive MBGs 
up to date. Nonetheless, the design of gated MBGs is highly appealing and might found 
a number of applications in advanced regenerative therapies.  
Based on these concepts, it was in our aim to demonstrate the possibility of preparing 
stimuli-responsive MBGs, via the implementation of tailor-made gated ensembles on 
the surface of bioactive glasses. The final goal was to develop bioactive glasses able to 
regenerate bone tissue in bone defects while treating the causal pathology of such a 
defect, for instance bone infection or tumor extirpation. Therefore the mesopores of a 
selected MBG were capped with two different enzyme-responsive molecular gates 
based in the use of adenosine triphosphate (ATP) and ε-poly-L-lysine as caps (vide 
infra), which allowed controlled cargo release in the presence of alkaline phosphatase 
(ALP) and proteolytic enzymes, respectively. Proteolytic activity can be observed in the 
presence of different infectious pathogens as Escherichia coli [39,40], whereas high 
levels of serum ALP have prognostic significance of osteosarcoma scenarios [41]. We 
envision that such tailor-designed systems may have potential applications for the 
treatment of bone tissue defects commonly associated to osteomyelitis and bone tumors 
extirpation. 
2. Materials and methods  
2.1 Chemicals 
The  chemicals tetraethyl orthosilicate (TEOS) (98%), triethyl phosphate (TEP) (99%), 
calcium nitrate  Ca(NO3)2·4H2O (99%), F68 (EO)78-(PO)30-(EO)78 triblock copolymer, 
tris(2,2’-bipyridyl)ruthenium(II) chloride hexahydrate ([Ru(bpy)3]2+), 3-[2-(2-
aminoethylamino)ethylamino]propyl-trimethoxysilane (N3), adenosine 5’-triphosphate 
disodium salt hydrate (ATP) (99%), N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide 
hydrochloride (EDC), alkaline phosphatase (ALP) from bovine intestinal 
mucosa(buffered aqueous glycerol solution, ≥6,500 DEA units/mg protein), 3-
(triethoxysilyl)propyl isocyanate, acetonitrile anhydrous (99.8%), hydrochloric acid 
(37%), levofloxacin (98%), Dulbecco’s Modified Eagle’sMedium and pronase enzyme 
from S. griseus were purchased from Sigma–Aldrich Química S.A. Triethylamine 
(TEA) (98%) was purchased from J.T. Baker Chemicals. ε-Poly-L-lysine was purchased 
from Chengdu Jinkai Biology Engineering Co., Ltd. Fetal Bovine Serum (FBS) was 
obtained from Gibco, BRL.LB medium was provided from Laboratorios Conda. L-
glutamine, penicillin and streptomycin were purchased from BioWhittaker-VWR 
Europe. Doxorubicin used was obtained from the European Pharmacopoeia Reference 
Standard (Council of Europe EDQM).  
2.2 General Techniques 
FTIR spectroscopy was carried out with a Nicolet Magma IR 550 spectrometer. TEM 
images were obtained with a 100 kV Jeol JEM-1010 microscope. SEM images were 
obtained with a 20kV JEOL F-6335 microscope. Differential thermal analysis was done 
in a TG/DTA Seiko SSC/5200 thermobalance between 50 °C and 1000 °C at a heating 
rate of 10°C·min-1. The textural properties of the calcined materials were determined by 
nitrogen adsorption porosimetry by using a Micromeritics ASAP 2020 porosimeter. To 
perform the N2 adsorption measurements, the samples were previously degassed under 
vacuum for 15 hours, at 150 °C. The surface area was determined using the Brunauer-
Emmett-Teller (BET) method. The pore size distribution between 0.5 and 40 nm was 
determined from the adsorption branch of the isotherm by means of the Barret-Joyner-
Halenda (BJH) method.1H-29Si and 1H-31P CP (cross-polarization)/MAS (magic-angle-
spinning) and single-pulse (SP) solid-state nuclear magnetic resonance (NMR) 
measurements were performed to evaluate the different silicon and phosphorus 
environments in the synthesized samples. The NMR spectra were recorded on a Bruker 
Model Avance 400 spectrometer. Samples were spun at 10 kHz for 29Si and 6 kHz in the 
case of 31P. Spectrometer frequencies were set to 79.49 and 161.97MHz for 29Si and 31P, 
respectively. Chemical shift values were referenced to tetramethylsilane (TMS) and 
H3PO4 for 29Si and 31P, respectively. The CP spectra were obtained using a proton 
enhanced CP method, at a contact time of 1 millisecond. The time period between 
successive accumulations was 5and 4seconds for 29Si and 31P, respectively, and the 
number of scans was 10000 for all spectra. Solid-state 
13
C spectra were obtained with a 
Bruker Model Avance 400 spectrometer 75.46 MHz. For the cell proliferation test, the 
absorbance was measured using a Helios Zeta UV-VIS spectrophotometer.  
2.3 Synthesis of mesoporous bioactive glasses functionalized  
2.3.1 Synthesis of the mesoporous bioactive glass (S1)  
85%SiO2-10%CaO-5%P2O5 (% mol) mesoporous glass (S1) was synthetized by 
evaporation induced self-assembly (EISA) method, using F68 (EO)78-(PO)30-(EO)78 
triblock copolymer as structure directing agent. TEOS, TEP and calcium nitrate 
Ca(NO3)2·4H2O were used as SiO2, P2O5 and CaO sources, respectively. In a typical 
synthesis, 2 g of F68 were dissolved in 30 g of ethanol with 0.5 ml of HCl 0.5 M 
solution at room temperature. Afterward, 3.70 g of TEOS, 0.34 g of TEP and 0.49 g of 
Ca(NO3)2·4H2O were added under stirring in 3 hours intervals. The resulting solution 
was stirred during 12 hours and casted into Petri dishes (9 cm in diameter). The 
colorless solution was evaporated at 30 °C during 11 days. Eventually, the dried gels 
were removed as homogeneous and transparent membranes, and heated at 700 °C for 3 
hours under air atmosphere. Finally the MBG powder was gently milled and sieved, 
collecting the particle size fraction below 40 µm. 
2.3.2 Synthesis of S2  
1 g of S1 was suspended in 30 mL of anhydrous acetonitrile under inert atmosphere. 
Then, 1 mL (3.88 mmol) of 3-[2-(2-aminoethylamino)ethylamino]propyl-
trimethoxysilane (N3) was added and the mixture was stirred for 5.5 hours. Finally, the 
solid was filtered, washed with H2O repeatedly and dried under vacuum for 12 hours.  
2.3.3 Synthesis of S3  
200 mg of solid S2 were suspended in a solution of EDC 0.1 M and ATP 1.8 M, 
previously adjusted to pH 7 with NaOH. The suspension was stirred for 6 hours at room 
temperature. The resulting solid was filtered and dried under vacuum for 12 hours.  
2.3.4. Synthesis of S4  
In a typical synthesis, 1 g of S1 was suspended in 50 mL of methanol, inside a round-
bottom flask under inert atmosphere. Then, an excess of 3-
(triethoxysilyl)propylisocyanate (isocyanate) (1 mL, 4 mmol) was added and the final 
mixture was stirred for 5.5 hours at room temperature. The solid was filtered, washed 
with H2O repeatedly, and dried under vacuum for 12 hours.  
2.3.5. Synthesis of S5  
A solution of 1 g of ε-poly-L-lysine (0.2 mmol) and TEA (1.6 mL, 11.5 mmol) in 20 mL 
of methanol was added onto the solid S4, and the mixture was stirred for 2 hours. 
Finally, the solid was filtered off and dried under vacuum. 
2.3.6. Synthesis of S3-Ru and S5-Ru 
In order to carry out the proof of concept about the functioning of ATP and ε-poly-l-
lysine based gates, both systems were loaded with a fluorescence dye. For this purpose 
2 g of S1 were suspended in a solution of 1.6 g tris(2,2’-bipyridil)ruthenium(II) chloride 
hexahydrate ([Ru(bpy)3]2+ dye in 70 mL of anhydrous acetonitrile in a round-bottomed 
flask. Then, 10 mL of acetonitrile were distilled with a dean-stark, in order to remove 
the possible water present in the pores of the solid. Afterwards, the mixture was stirred 
at room temperature during 24 hours, in order to achieve maximum loading in the pores 
of the MBG scaffolding. The resulting solid was then filtered and dried under vacuum 
for 12 hours. Subsequently, the solid was functionalized and capped as S3 and S5 
respectively, as described above. Once dried, the solids were suspended in 5 mL of 
water and stirred in short washing, in order to remove the excess of dye remaining on 
the surface of the materials. The solids were filtered again and dried under vacuum for 
12 hours. 
2.3.7. Synthesis of S3-Levo and S5-Levo 
In order to test the functioning of ATP and ε-poly-L-lysine based gates as on command 
antibiotic delivery devices, both systems were loaded with levofloxacin. For this 
purpose 800 mg of S1 were suspended in a solution of 400 mg (1.11 mmol) of 
levofloxacin in 20 mL of methanol inside a round-bottom flask under inert atmosphere. 
The mixture was stirred at room temperature during 24 hours to achieve maximum 
loading in the pores of the MBG. Subsequently, the solution was split in two and each 
part was functionalized in a similar way to S3 and S5 respectively. Finally S3-Levo and 
S5-Levo were washed in water to remove the excess of antibiotic remaining on the 
surface. 
2.3.8. Synthesis of S3-Dox 
In order to test the functioning of the ATP based gate as on command antitumoral 
delivery devices, 30 mg of solid S2 and 6 mg of doxorubicin were suspended in 5mL of 
methanol and stirred for 50 hours. Then, the solid was centrifuged and dried under 
vacuum for 1 hour. Finally the solid was introduced in a solution of EDC 0.1 M and 
ATP 1.8 M previously adjusted to pH 7 with NaOH. The suspension was stirred for 6 
hours at room temperature. The resulting solid was centrifuged, washed several times 
with water and methanol and dried under vacuum for 12 hours.  
Table 1 contains a summary of the synthesized solids.  
2.4 Stimuli-responsive studies  
2.4.1 Stimuli-responsive studies with S3-Ru and S5-Ru 
4 mg of the S3-Ru and S5-Ru were suspended in 10 mL of water, and the pH was 
adjusted to 7.6 with NaOH. Both suspensions were split in two in order to study the dye 
release in the absence or presence of the corresponding stimuli, i.e. ALP and pronase for 
S3-Ru and S5-Ru, respectively. The two samples were stirred at 400 rpm and 37°C, and 
then several 250µL aliquots were taken for each sample at different times. These 
aliquots were filtered with PFTE filters (0.22 µm) to monitor the [Ru(bpy)3]2+ release 
(λex 454 nm, λem 593 nm) by fluorescence spectroscopy 
2.4.2 Stimuli-responsive studies with S5-Levo 
4 mg of S5-Levo were suspended in 10 mL of water, and the pH was adjusted to 7.6 
with NaOH. The suspension was split in two in order to study the levofloxacin release 
in the absence and the presence of E.coli (final concentration 105 cells mL-1). The two 
samples were stirred at 400 rpm and 37 °C, and then several 250µL aliquots were taken 
for each sample at different times. These aliquots were filtered with PFTE filters (0.22 
µm) to monitor the levofloxacin release (λex 292 nm, λem 494 nm) by fluorescence 
spectroscopy. 
2.4.3 Stimuli-responsive studies with S3-Dox 
4.6 mg of S3-Dox were suspended in 2 mL of H2O pH 7.6. Then, 0.5 mL of this 
suspension was placed on a Transwell permeable support with polycarbonate membrane 
(0.4 μm). The well was filled with 1.5 mL of H2O pH 7.6 and the suspension was stirred 
at 37 °C and 100 rpm during all the experiment. To study the enzymatic responsiveness 
of the solid, the suspension was in contact with ALP on a Transwell. The amount of 
cargo released was determined by fluorescence spectrometry λexc 490, λem 514 nm, and 
the solution outside the Transwell insert was replaced with fresh medium, with or 
without ALP. 
2.5 Bioactivity assays with solids S3 and S5 
Assessments of in vitro bioactivity were carried out on S3 and S5 solids. For this 
purpose, 40 mg of the solids were soaked into 6 mL of filtered simulated body fluid 
(SBF) [46] in polyethylene containers at 37 °C under sterile conditions [38]. The 
evolution of the solids surfaces were analysed by Fourier transform infrared (FTIR) 
spectroscopy and scanning electron microscopy (SEM). 
 
2.6 Biological assessment of the gated materials 
2.6.1 E. coli DH5α culture conditions 
For viability studies, bacteria Escherichia coli (E. coli), cell culture DH5α was used. 
Bacteria cells were maintained in glycerol 15% at -80 °C. For the assays, cells were 
grown for 24 hours at 37 °C and under constant stirring with 5 mL of LB medium. Cells 
from 1 mL culture were collected by centrifugation for 30 seconds at 13000 rpm and 
resuspended in 1 mL of milliQ water at pH 7.6. Then a dilution of 2·104 cells·mL-1 was 
prepared, in order to achieve a final concentration of 104 cells·mL-1. The same 
procedure was carried out for both kinetic and viability assays.  
2.6.2 Clonogenic cell viability assay with S5-Levo, levofloxacin and ε-poly-L-lysine 
For the clonogenic cell viability assay with S5-Levo, different suspensions of S5-Levo 
containing bacteria (final concentration 104 cells·mL-1) were prepared, achieving the 
final solid concentrations of 800, 500, 300, 200, 160, 120, 80, 60, 40, 20, 10, 5, 1 and 0 
µg solid·mL-1. The samples were stirred at 180 rpm (37 °C) during 10 minutes. Then, 
the suspensions were suitably diluted with milliQ water (pH 7.6) in order to obtain a 
cell growth easy to quantify. Finally, 100 µL of the new dilutions were seeded in LB 
plates (3% agar) and incubated at 37°C for 24 hours. Then, Colony Formation Units 
(CFU) were quantified.  
To test the cytotoxicity of the non-loaded ε-poly-L-lysine capped solid (S5), the same 
experiment was carried out with final solid concentratons of 600, 300, 200, 100, 50, 30, 
20, 5 and 0 µg solid·mL-1. 
To determine the cytotoxicity of free levofloxacin and free ε-poly-L-lysine, final 
concentrations of 2000, 1000, 800, 600, 400, 300, 250, 200, 150, 100, 60, 30, 10 and 0 
ng·mL-1 (levofloxacin) and 600, 400, 200, 100, 80, 50, 40, 30, 10 and 0 ng·mL-1 (ε-
poly-L-lysine) were achieved. In order to test the specificity of the gates, solid S3-Levo 
(capped with ATP) was submitted to the same procedure. 
2.6.3 Human Osteosarcoma (HOS) cells culture test 
HOS cells were seeded on well culture plates (CULTEK), at a density of 40000 cell per 
mL in Dulbecco’s Modified Eagle’s Medium with 10% foetal bovine serum, 1 mM L-
glutamine, penicillin (200 mg·mL-1), and streptomycin (200 mg·mL-1), under a CO2 
(5%) atmosphere at 37 °C, 24 hours to reach the confluence in each cell plate. 
Thereafter, S3-Dox solid was added on the seed cells at half confluence at 200µg·mL-
1concentration.In order to study the stimuli-responsive behaviour of the ATP gate, ALP 
was added to the culture wells to simulate a scenario of ALP activity excess. 
2.6.4 Cell proliferation test 
Cell proliferation in contact with S3 and S3-Dox was determined by the MTT method. 
Samples were incubated for 4 hours at 37 °C and 5% CO2 under dark conditions. Then, 
the medium was removed and 0.5 mL of isopropanol–HCl solution were added. Finally, 
the absorbance was measured at 460 nm. 
2.7 Statistics 
Statistics Data are expressed as means-standard deviations of experiments. Statistical 
analysis was performed using the Statistical Package for the Social Sciences (SPSS) 
version 22 software (IBM). Statistical comparisons were made by analysis of variance 
(ANOVA). Subsequently, post hoc analyses were carried out to correct for multiple 
comparisons. In all of the statistical evaluations, P<0.01 was considered as statistically 
significant. 
3. Results and discussion 
3.1 Characterization results 
The synthesis strategies developed in this work are aimed to design multifunctional 
bioceramics with two main features. The first one is the stimulation of bone tissue 
regeneration to restore the skeletal integrity in bone defects. In this sense, the material 
should exhibit high bioactive behavior, that is, the capability to osteointegrate with the 
host tissue through the formation of an apatite-like phase on its surfaces. The second 
function is to deliver drugs on demand to treat the causal pathology of the bone defect, 
for instance bone infection or extirpated bone tumors. In order to reach these goals we 
have designed two different on demand drug delivery systems, depicted in Scheme 1. 
The first one has been designed on the basis that ATP molecules acted as capping 
agents. For this purpose ATP formed a covalent bond with the triamine attached to the 
external surface of the mesoporous material, capping the pores and inhibiting cargo 
release (solid S3). Conveniently, hydrolysis of ATP molecules induced by the over-
activity of external ALP would uncap the mesopores, allowing cargo delivery in a 
controlled and selective way. The second system was designed by functionalizing the 
external surface of the MBG with 3-(triethoxysilyl)propyl isocyanate (S4). The resulting 
solid was treated with ε-poly-L-lysine, to form urea bonds with the isocyanate groups 
attached to the external surface to yield the final material S5. ε-poly-L-lysine would 
cover the surface of the loaded solid, capping the entrance to the pores and inhibiting 
payload release. Otherwise, the presence of bacterial proteases would induce hydrolysis 
of the amide bond in ε-poly-L-lysine, allowing cargo release. A diagram of all the 
prepared solids is shown in Scheme 2.  
FTIR spectroscopy was carried out after each functionalization stage, confirming the 
presence of the corresponding functional groups for solids S1, S2, S3, S4 and S5 (see 
Figure S2 in Supporting Information). 
The MBG functionalization was followed by solid state NMR to confirm the successful 
incorporation of the different components of the gates. Figure 1 shows solid-state 29Si 
single pulse (left) and cross-polarization (right) MAS NMR spectra for solids S1, S3 
and S5. These experiments were used to evaluate the presence of the organosilanes 
linkers bonded to the MBG surface. In solid S1, single pulse spectrum shows three 
signals corresponding to Qn inorganic silica environment. The observed chemical shifts, 
listed in Table S1 (see Supporting Information) showed signals corresponding with Q4 
between -109 and -112 ppm, Q3 between -100 and -103 ppm and Q2 between -91 and -
94 ppm. In solid S3, the resonances at around -58 and –67 ppm represent silicon atoms 
in positions (≡SiO)2Si(OH)R and (≡SiO)3SiR, denoted as T2 and T3, respectively, 
evidencing the covalent functionalization with 3-[2-(2-
aminoethylamino)ethylamino]propyl-trimethoxysilane. These signals are emphasized in 
the CP spectra pointing out that the liker is mainly located at the MBG surface. In the 
case of solid S5, the functionalization with 3-(triethoxysilyl) propylisocyanate seems to 
be lower, as SP spectra does not shown Tn signals and only CP spectra evidenced the 
presence of this organosilane at the surface of S5 [42]. 
Solid-state 31P single pulse MAS NMR spectra for sample S3 were used to evaluate the 
local environment of P (Figure 2). The band at 1.8 ppm is associated with inorganic 
PO4 tetrahedrons within silica network. Bands at -7.2, -12.0 and -20.6 ppm are assigned 
to α, β and γ P atoms of the ATP molecules bounded. The higher intensity of the signal 
at -7.2 ppm is attributed to the convolution of the Pγ of ATP with the q1 signal 
corresponding to environmental P-O-Si bonds [43,44].  
Solid-state 1H 13C-CPMAS for solids S3 and S5 are shown in Figure 3. The spectra 
provide clear evidence that both solids were functionalized with their corresponding 
gates. Solid S3 presents characteristic bands of amino-carbon bond associated with 3-
[2-(2-aminoethylamino)ethylamino]propyl-trimethoxysilane between 10 and 60 ppm. 
Characteristic bands of ATP appear from 60 ppm and correspond with the carbons of 
ribose and the aromatic heterocycle. S5 shows bands associated with 3-
(triethoxysilyl)propylisocyanate and isocyanate carbon no reacted of S4. The spectra 
also show characteristic band of ε-poly-L-lysine as amide carbons at 170 ppm.[45] The 
assignations of carbons are summarized in Table S2 (Supporting Information). 
The mesoporous structure of the different solids was confirmed by TEM (Figure 4). 
The characteristic channels of a mesoporous ordering matrix were observed as alternate 
black and white stripes, evidencing highly ordered mesoporous structures in all solids, 
assignable to a pseudo-hexagonal group (assessed by powder X-ray diffraction 
measurements, see Supplementary Material, figure S1). These results demonstrate that 
the loading and capping processes undergone by the MBG did not significantly affect 
the mesoporous ordering.  
The N2 adsorption-desorption isotherms of S1 show a type IV curve, characteristic of 
mesoporous materials (Figure 5). The curve shows a H1 hysteresis loop indicating that 
mesopores have an opened at both ends cylinder morphology. Solids S3-Ru and S5-Ru 
exhibit isotherms corresponding to mesoporous materials with lower surface area and 
pore volume, as could be expected after loading with [Ru(bpy)3]2+ and subsequent 
capping with the ATP (solid S3-Ru) or ε-poly-L-lysine (solid S5-Ru) based gates (see 
Table 2). Solid S3-Ru shows a strong decrease of textural values respect to pristine 
solid S1. In fact, the hysteresis loop changes to type H2 pointing out that the mesopore 
morphology shifts from open cylinders towards ink-bottle morphology as a 
consequence of the highly effective capping with the ATP gate. On the other hand, the 
textural parameters of solid S5-Ru underwent a lower decrease of textural parameters. 
The higher organic content of solid S3-Ru compared to S5-Ru calculated from 
thermogravimetry would justify the different decrease of porosity observed in these 
solids (see Figure S2 in Supporting Information for further details).  
3.2 Kinetic studies 
In order to investigate the gating properties of ATP and ε-poly-L-lysine gates, cargo-
release studies were carried out with S3-Ru and S5-Ru. In a typical experiment, 2 mg 
of S3-Ru were suspended in water at pH 7.6 in the presence and absence of ALP. 
Suspensions were stirred at 400 rpm at 37 °C for 10 hours, and at given time intervals 
fractions of both suspensions were taken and filtered to remove the solid. Dye released 
to the solution was then monitored by measuring the fluorescence of [Ru(bpy)3]2+ at 594 
nm (λex 454 nm). [Ru(bpy)3]2+ delivery profiles in both, the presence and absence of 
ALP enzyme, are shown in Figure 6A. A negligible dye release occurs when ALP is not 
present. Contrarily, the concentration of [Ru(bpy)3]2+ in the solution increased 
significantly in the presence of the enzyme. This behavior is consistent with a tight pore 
closure by ATP, which would be hydrolyzed in the presence of ALP, thus unblocking the 
entrance to the pores and allowing cargo release.  
Similar release studies were also performed with the ε-poly-L-lysine-capped solid S5-
Ru but using pronase enzyme as trigger (Figure 6B). Delivery profiles in both, the 
presence and absence of pronase enzyme are shown in Figure 6B. A poor [Ru(bpy)3]2+ 
release was observed in the absence of pronase, while a significant increase of payload 
delivery occurs when the enzyme is added to the medium. The differences in both 
release kinetics are due to the fact that two different capping systems and enzymes are 
being used. ε-poly-L-lysine is a long polymer with a number of amide bounds to be 
hydrolised, yielding L-lysine molecules. The action of the pronase enzyme allows a fast 
hydrolysis of the molecular gate and a quick leakage of the dye out of the pores. 
However, alkaline phosphatase is expected to hydrolyze the phosphate groups of ATP. 
This anion, in solid S3-Ru, is coordinated with positively charged amino moieties 
located onto a dense network of polyamines grafted onto the outer surface of the loaded 
support. For this reason, alkaline phosphatase could have some steric hindrance in the 
hydrolysis of the phosphate groups of ATP and, as a consequence, a slower release of 
the dye was observed. 
These experiments confirm that ε-poly-L-lysine is a suitable capping system in MBG 
supports, which can be hydrolysed in the presence of pronase enzyme, thus resulting in 
cargo release. 
3.3 In vitro bioactivity tests 
MBGs are featured by their excellent bioactive properties. Their high surface area and 
porosity enhance the ionic exchange with the surrounding media, thus developing an 
apatite-like phase onto their surface that ensures the integration with the bone under in 
vivo conditions. Up to date, MBGs have demonstrated to be the fastest bone grafts in 
developing this apatite like phase. However, the bioactivity of MBGs can be seriously 
harmed if the textural properties are modified. The ATP and ε-poly-L-lysine based gates 
keep the mesopores capped until the enzymatic stimuli open them. Thus, we decided to 
assess the bioactive behavior of solids S3 and S5. For this purpose, both solids were 
soaked in simulated body fluid (SBF) at 37 °C to test their capability for nucleating and 
growing a newly formed apatite-like phase. The tests were carried out in absence and 
presence of the corresponding enzymatic stimuli. Solid S3 does not develop any newly 
formed calcium phosphate layer when soaked in SBF for 3 days, in absence of stimuli. 
The SEM micrographs do not evidence significant changes at the MBG surface (Figure 
7A and 7B). However, in the presence of ALP, i.e. when the gate is open, the MBG 
recovers the bioactive behavior and develops an apatite like phase after 1 day in SBF 
(not showed in this manuscript), which further grows after 3 days in contact with this 
solution (Figure 7C ). Figure 7D at high magnification shows typical morphology 
apatite layer.  FTIR spectroscopy agrees with the SEM results in the absence and 
presence of ALP (Figure 7I). In the absence of ALP, the spectra show the same 
absorption bands before and after soaking in SBF, i.e those corresponding to the 
vibrations of Si-O bonds and P-O bonds in amorphous environment. On the contrary, in 
the presence of ALP, the FTIR evidence the splitting of the signal at 590-610 cm-1 in the 
FTIR spectra, pointing out that the newly phase observed by SEM is an apatite-like 
phase (Figure 7D). In addition EDS results confirm a relation Ca/P= 1.66, similar 
relation Ca/P to apatite phase.  
On the other hand, solid S5 exhibits an excellent bioactive behavior. This solid develops 
a thick newly formed apatite phase in both the presence and absence of enzymatic 
stimuli, as evidenced by SEM (Figure 7F, 7G and 7H), EDS with a relation Ca/P=1.76 
and confirmed by the doublet at 590-610 cm-1 appeared in the FTIR spectra (Figure 
7J). 
The inhibition of the bioactive behavior after the incorporation of the ATP gate could be 
related with the significant decrease of textural properties undergone by the MBG. The 
functionalization strategy used for the preparation of S3 was very efficient, as could be 
observed by NMR and porosimetry measurements. The capping of the mesopores would 
impede the ionic exchange with the surrounding SBF thus avoiding the subsequent 
nucleation and growth of the newly formed apatite phase. In order to find out the 
significance of this effect, we analyzed the Ca2+-H+ exchange of this solid during the 
first stages of the bioactive process (Figure S3). The Ca2+ release from solid S3 to the 
SBF is significantly decreased compared with MBG without capping. Ca2+ release is the 
first reaction required to initiate the bioactive process [46,47]. The inhibition of this 
stage seriously hiders the rest of the reactions that lead to the formation of an apatite-
like phase similar to the mineral component of the bone. Another possible explanation 
could be the entrapping of Ca2+ by the phosphate groups of the ATP gate. It has been 
highly demonstrated that the affinity of phosphate groups for Ca2+ can inhibit its release 
(and consequently the bioactivity) by forming CaP nanoclusters that inhibit the Ca2+ 
dissolution. The CaP clusters formation has been widely studied within the walls of the 
MBGs [48–51] and we hypothesize that the Ca2+ entrapment by phosphates could also 
occurs at the MBG surface due to the ATP presence. Independently of the mechanism 
that inhibits the bioactivity of S3, ALP open the ATP based gate and the MBG recovers 
its bioactivity. 
3.4 Biological assessment of the gated materials 
In order to test the proper working of the gatting scafold of S3-Dox before the stuies in 
biologial environments, controlled release of Dox in the absence and in the presecen of 
alkaline phosphatase were carried our. As could be seen in Figure 8, in the absence of 
enzyme negligible drug release was observed. However, when alkaline phosphatase was 
added a marked Dox release was obserbed  ascribed to the hydrolysis of ATP with 
sugsequent pore opening. Then, the antitumoral activity of S3-Dox was studied with 
HOS cell cultures. HOS viability was measured in the presence of S3 and S3-Dox under 
absence and presence of ALP (Figure 9). The cells in contact with S3 show a 
proliferative behaviour very similar to those cultured on the polystyrene control. 
However, the cells cultured with S3-Dox clearly underwent a cytotoxic effect. In the 
absence of ALP, the HOS proliferation is significantly hampered after 24 hours respect 
to the control. This result can be due to the small amount of doxorubicin released, even 
without the addition of ALP. It must be taken into account that HOS cells produce ALP 
by themselves and could facilitate the partial opening of the ATP gates. However, 48 
hours later HOS proliferate indicanting that the doxorubicin released is not enough to 
inhibit the growth of this tumoral cells. On the contrary, in the presence of ALP, HOS 
cannot proliferate after 48 hours of culture showing a significant viability decrease as a 
consequence of the released doxorubicin. (The complete studyat 144 h is described in 
the supplementary information in section 5). 
In a second scenario, the MBG solid capped with ε-poly-L-lysine was loaded with the 
antibiotic levofloxacin (solid S5-Levo) and the selective delivery of the antibiotic in the 
presence of bacteria was evaluated. For this study Escherichia coli, DH5α strain, was 
used as model bacteria. In a first step, the amount of cargo released from S5-Levo was 
determined in the presence and in the absence of bacteria. As shown in Figure 10, a 
limited payload delivery (less than 20% after 25 hours) was found in the absence of E. 
coli, whereas a remarkable cargo delivery was found when the bacteria were present. 
From these studies it was found that maximum amount of levofloxacin released from 
S5-Levo was of 0.322 ng of levofloxacin per mg of solid. Moreover, it was also 
observed that delivery of antibiotic levofloxacin was concomitant with a reduction of 
bacteria viability (vide infra). 
The antimicrobial activity of S5-Levo was studied more in detail by carrying 
clonogenic cell-viability assays in which E. coli bacteria were treated with different 
concentrations of S5-Levo at pH 7.6. A negative assay with no bacteria was also carried 
out and used as control to quantify cell growth. In a typical experiment, bacteria (104 
cells·mL-1) were incubated for 5 minutes in the presence of S5-Levo, and then seeded in 
petri plates. Seeded plates were incubated at 37 °C for 24 hours and then colony 
formation units (CFU) were quantified. Figure 11 shows %CFU versus the maximum 
amount of levofloxacin that can be released from S5-Levo (i.e. 0.322 ng of levofloxacin 
per mg of solid, vide ante). As seen in the figure, CFU values were correlated with the 
amount of S5-Levo added to the bacteria medium. S5-Levo showed considerable 
toxicity against E. coli, with an EC50 value of 22.26 ng·mL-1. Additionally, to 
demonstrate that the antibiotic effect found for S5-Levo was due to the release of 
levofloxacin in the presence of E. coli, similar experiments were carried out with a 
MBG support also capped with ε-poly-L-lysine but that did not contain levofloxacin 
(solid S5). This solid showed negligible toxicity against bacteria (data not shown), 
strongly suggesting that the delivery of antibiotic levofloxacin from S5-Levo was the 
responsible for bacterial death. Moreover, in a further experiment the toxicity of solid 
S5-Levo was compared to that of free levofloxacin and free ε-poly-L-lysine. As 
depicted in Figure 11, levofloxacin and ε-poly-L-lysine showed similar toxicity to E. 
coli with EC50values of 151.99 ng·mL-1 and 131.37 ng·mL-1, respectively. This is a 
remarkable result that indicated that levofloxacin is seven-fold more toxic when 
entrapped in S5-Levo than when free.  
The toxic effect observed for S5-Levo described above against E. coli can be 
understood keeping in mind that ε-poly-L-lysine molecules can be hydrolyzed by 
proteolytic enzymes excreted by the bacteria [52] which would result in levofloxacin 
delivery. In order to demonstrate that protease activity of E. coli was the responsible of 
the release of levofloxacin via degradation of the ε-poly-L-lysine cap, parallel 
experiments were performed with solid S3-Levo. This is a MBG support loaded with 
the antibiotic levofloxacin and capped with the ATP gate-like ensemble described 
above. As the ATP gate cannot be degraded by proteases, it was expected that this solid 
would not be toxic for E. coli. The antimicrobial activity of solid S3-Levo was studied 
following a similar protocol to that described above for S5-Levo. However, in this case, 
no remarkable toxicity to E. coli was found after treating bacteria with S3-Levo and no 
levofloxacin delivery was observed. 
4. Conclusions 
In conclusion, it has been demonstrated that MBGs can be functionalized and 
implemented with tailored molecular gates, allowing a new application as controlled 
delivery device. Specifically, two different solids were prepared from a MBG selected 
as an inorganic support. One portion was functionalized with a triamine and capped 
with ATP, whereas the other portion was functionalized with isocyanates and capped 
with ε-poly-L-lysine. Solids following each step were correspondingly characterized, 
finding evidence of their correct functionalization with the tailored molecular gates. 
Both molecular gated mechanisms were proved to be opened, in the presence of the 
corresponding enzymes (ALP and pronase, respectively), while they remained closed in 
the absence of the stimuli. Moreover, we have demonstrated the different bioactive 
behavior in both gated solids. Whereas ε-poly-L-lysine-capped system allows the 
formation of crystalline hydroxyapatite on their surface under any scenario, the ATP-
capped system requires the opening of the molecular gate to initiate the formation of the 
apatite phase. 
Finally, the in vitro efficiency of both gated systems was validated. The ATP-capped 
system responds to the presence of high levels of ALP, opening the gates and releasing 
doxorubicin. Higher serum ALP levels are found in patients developing osteosarcoma 
and our ATP-capped system has demonstrated to inhibit the HOS cells proliferation 
under a similar scenario. Regarding the ε-poly-L-lysine-capped system, we 
demonstrated that the presence of E.coli bacteria was also able to hydrolyze the ε-poly-
L-lysine gate, allowing levofloxacin release. Therefore, we also tested the cytotoxic 
effect of the solid, and demonstrated that equitoxic concentration of the levofloxacin 
contained in the solid was more effective against bacteria than free levofloxacin and 
free ε-poly-L-lysine. We also proved that the capped solid performed no cellular 
damage when there was no levofloxacin inside the pores, which evidences that the 
cytotoxicity is totally caused by the released levofloxacin.  
Thus, we have envisioned here a new approach to mesoporous gated materials, which is 
expected to set up innovative pathways to the treatment of bone diseases. 
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Figure caption 
 
Scheme 1. Schematic representation of the ATP (A) and ԑ-poly-L-lysine (B) molecular 
gates. 
Scheme 2. Flow diagram showing the preparation and name of the solids used in this 
paper.  
Figure 1. Solid-state 29Si single-pulse (left) and cross-polarization (right) MASNMR 
spectra of S1, S3 and S5 solids. The areas for the Qn units were calculated by Gaussian 
line-shape deconvolutions (their relative populations are expressed as percentages). 
Figure 2. Solid-state 31P single-pulse MASNMR spectra (with their respective 
phosphorus environments shown at the top) of solid S3. 
Figure 3. Solid-state 13C single-pulse MASNMR spectra (with their respective carbon 
environments shown at the top) of solids S3 and S5. * Signal assigned to unreacted 
isocyanate groups. 
Figure 4. Representative TEM images of solids S1, S4 and S5. 
Figure 5. N2 adsorption-desorption isotherms for solids S1, S3-Ru and S5-Ru. 
Figure 6. Kinetic dye release studies carried out at 37 °C A) MBG capped with ATP 
(S3-Ru), B) MBG capped with ԑ-poly-L-lysine (S5-Ru).   
Figure 7. SEM micrographs of solid S3 in absence of stimuli, A) before soaking, B) 
when is soaked in SBF for 24 hours and C) 72 hours. SEM micrographs of solid S3 in 
presence of stimuli, D) when is soaked in SBF for 24 hours and E) 72 hours. SEM 
micrographs of solid S5 in absence of stimuli, G) before soaking, H) when is soaked in 
SBF for 24 hours and I) 72 hours. SEM micrographs of solid S5 in presence of stimuli, 
J) when soaked in SBF for 24 hours and K) 72 hours. FTIR spectra for solids F) S3 and 
L) S5. 
Figure 8. Kinetic doxorubicin release studies carried out at 37 °C with S3-Dox in the 
presence and in the absence of ALP. 
Figure 9. HOS viability in contact with S3 and S3-Dox solids in the absence and 
presence of ALP after 6, 24 and 48 h n=3 control   Significant differences from 48 
hours: *p<0.05, **p<0.01. Statistical significance: * p<0.05, **p<0.01    
Figure 10. Kinetic levofloxacin release studies carried out at 37 °C with S5-Levo in the 
presence and in the absence of E. coli. 
Figure 11. Free levofloxacin (•), free ε-poly-L-lysine (○), equitoxic concentration of 
levofloxacin in S5-Levo (▀) and equitoxic concentration of levofloxacin in S3-Levo (▲) 
versus %CFU.  
 
